Demographic Factors and the Presence of Comorbidities do not Promote Early Detection of Cushing's Disease and Acromegaly

 

 Buy Article Permissions and Reprints

Abstract

Objective: The aim of the study was to analyze the time-to-diagnosis interval in patients with Cushing's disease (CD) and acromegaly (AC), to assess factors that promote early disease detection and to investigate the medical fields diagnosing the pathologies.

Methods: 33 CD and 52 AC patients operated over 10 years received a self-designed disease-related questionnaire. Data about symptoms and their duration prior to diagnosis, education level, age, gender and place of residence (i. e. rural vs. urban, size of the city) were collected.

Results: The mean time-to-diagnosis interval was 6.0 years in CD and 5.8 years in AC patients. The vast majority of 67% of all investigated patients was diagnosed after they changed their primary health care provider or during a hospital stay owing to comorbidities caused by their underlying disease. Only 33% of all cases were diagnosed by their primary physician. In both groups neither gender, age, place of residence, education level, typical comorbidities (e. g. hypertension or diabetes) nor distinctive symptoms and bodily changes of the underlying disease (e. g. prognathism, acral enlargement, weight gain, buffalo hump) were significant factors promoting early detection.

Conclusions: Apparently, patient-related factors do not affect the time-to-diagnosis interval, but rather the change of the primary health care provider. Knowledge of the disease among physicians is prerequisite to early detection. Due to the deleterious sequelae of delayed diagnosis, information programmes in the medical community are of paramount importance. Institution of screening programmes should be evaluated.

References

• 1 Alexander L, Appleton D, Hall R. et al . Epidemiology of acromegaly in the Newcastle region.  Clin Endocrinol. 1980;  12 71-79
  Google Scholar
• 2 Arnaldi G, Angeli A, Atkinson AB. et al . Diagnosis and complications of Cushing's syndrome: a consensus statement.  J Clin Endocrinol Metab. 2003;  88 5593-5602
  Google Scholar
• 3 Bengtsson BA, Eden S, Ernest I. et al . Epidemiology and long term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.  Acta Med Scand. 1988;  223 327-335
  Google Scholar
• 4 Bogazzi F, Battolla L, Spinelli C. et al . Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study.  J Clin Endocrinol Metab. 2007;  92 4271-4277
  Google Scholar
• 5 Boscaro M, Barzon L, Fallo F. et al . Cushing's syndrome.  Lancet. 2001;  357 783-791
  Google Scholar
• 6 Cavagnini F, Pecori Girald F. Epidemiology and follow-up of Cushing's disease.  Ann Endocrinol. 2001;  62 168-172
  Google Scholar
• 7 Coculescu M, Niculescu D, Lichiardopol R. et al . Insulin resistance and insulin secretion in non-diabetic acromegalic patients.  Exp Clin Endocrinol Diabetes. 2007;  115 308-316
  Google Scholar
• 8 Daly AF, Petrossians P, Beckers A. An overview of the epidemiology and genetics of acromegaly.  J Endocrinol Invest. 2005;  28 (Suppl) 67-69
  Google Scholar
• 9 De P, Evans LM, Scanlon MF. et al . Osler's phenomenon: misdiagnosing Cushing's syndrome.  Postgrad Med J. 2003;  79 594-596
  Google Scholar
• 10 Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach.  Clin Endocrinol. 1993;  40 479-484
  Google Scholar
• 11 Etxabe J, Gaztambide S, Latorre P. et al . Acromegaly: an epidemiological study.  J Endocrinol Invest. 1993;  16 181-187
  Google Scholar
• 12 Findling JW, Raff H. Cushing's syndrome: important issues in diagnosis and management.  J Clin Endocrinol Metab. 2006;  91 3746-3753
  Google Scholar
• 13 Holdaway IM, Rajasoorya C. Epidemiology of acromegaly.  Pituitary. 1999;  2 29-41
  Google Scholar
• 14 Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly.  J Clin Endocrinol Metab. 2004;  89 667-674
  Google Scholar
• 15 Kauppinen-Mäkelin R, Sane T, Reunanen A. et al . A nationwide survey of mortality in acromegaly.  J Clin Endocrinol Metab. 2005;  90 4081-4086
  Google Scholar
• 16 Melmed S, Colao A, Barkan A. et al . Guidelines for acromegaly management: an update.  J Clin Endocrinol Metab. 2009;  94 1509-1517
  Google Scholar
• 17 Molitch M. Clinical manifestations of acromegaly.  Endocrinol Metab Clin North Am. 1992;  21 597-614
  Google Scholar
• 18 Monson JP. The epidemiology of endocrine tumours.  Endocr Relat Cancer. 2000;  7 29-36
  Google Scholar
• 19 Nabarro JD. Acromegaly.  Clin Endocrinol. 1987;  26 481-512
  Google Scholar
• 20 Nachtigall L, Delgado A, Swearingen B. et al . Extensive clinical experience: Changing patterns in diagnosis and therapy of acromegaly over two decades.  J Clin Endocrinol Metab. 2008;  93 2035-2041
  Google Scholar
• 21 Pereira AM, van Thiel SW, Lindner JR. et al . Increased prevalence or regurgitant valvular heart disease in acromegaly.  J Clin Endocrinol Metab. 2004;  89 71-75
  Google Scholar
• 22 Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's Syndrome.  Am J Med. 1952;  13 597-614
  Google Scholar
• 23 Reimondo G, Pia A, Allasino B. et al . Screening for Cushing's syndrome in adult patients with newly diagnosed diabetes mellitus.  Clin Endocrinol. 2007;  67 225-229
  Google Scholar
• 24 Ross EJ, Linch DC. Cushing's syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis.  Lancet. 1982;  2 646-649
  Google Scholar
• 25 Swearingen B, Barker FG, Katznelson L. et al . Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.  J Clin Endocrinol Metab. 1998;  10 3419-3426
  Google Scholar

Correspondence

T. PsarasMD 

Department of Neurosurgery

University of Tuebingen

Hoppe-Seyler-Straße 3

72076 Tuebingen

Germany

Phone: +49/07071/29 86742

Fax: +49/07071/29 5245

Email: tsambika.psaras@med.uni-tuebingen.de